Cellular Immunology Unit, Program of Immunology, Gene Therapy and Bio-Immunotherapy of Cancer, San Raffaele Scientific Institute, via Olgettina 58, 20132, Milan, Italy.
Cancer Immunol Immunother. 2012 Apr;61(4):453-68. doi: 10.1007/s00262-012-1216-6. Epub 2012 Feb 14.
The recent FDA approval of the first therapeutic vaccine against prostate cancer has revitalized the public interest in the fields of cancer immunology and immunotherapy. Yet, clinical results are modest. A reason for this limited success may reside in the capacity of the tumor to convert inflammation in a tumor-promoting condition and eventually escape immune surveillance. Here we present the main known interactions between the prostate tumor and the immune system, showing how the malignancy can dodge the immune system by also exerting several immunosuppressive mechanisms. We also discuss experimental and clinical strategies proposed to counteract cancer immune evasion and emphasize the importance of implementing appropriate murine models like the transgenic adenocarcinoma of the mouse prostate model for investigating the biology of prostate cancer and novel immunotherapy approaches against it.
最近 FDA 批准了首个用于前列腺癌的治疗性疫苗，这重新激发了公众对癌症免疫学和免疫疗法领域的兴趣。然而，临床结果并不显著。这种有限成功的原因之一可能在于肿瘤将炎症转化为促进肿瘤生长的条件，并最终逃避免疫监视的能力。在这里，我们介绍了前列腺肿瘤与免疫系统之间的主要已知相互作用，展示了恶性肿瘤如何通过发挥几种免疫抑制机制来躲避免疫系统。我们还讨论了为对抗癌症免疫逃逸而提出的实验和临床策略，并强调了实施适当的小鼠模型（如转基因小鼠前列腺癌模型）的重要性，以便研究前列腺癌的生物学和针对它的新型免疫疗法。
